A new study has shed light on the impact of Alzheimer’s disease (AD) on the retina. The study, conducted by an international team of researchers, found that AD pathology affects not only the brain but also the neurosensory retina. The findings, published in the journal Acta Neuropathologica, have important implications for the early detection and monitoring of AD, as the retina offers unparalleled accessibility for direct, affordable, and noninvasive visualisation and temporal monitoring of central nervous system (CNS) targets.
AD is a devastating neurodegenerative disorder and a major cause of morbidity and mortality worldwide. The hallmark signs of AD, cerebral amyloid β-protein (Aβ) plaques and neurofibrillary tangles (NFTs) comprised of hyperphosphorylated (p)Tau, are prerequisites for a definitive AD diagnosis and have been shown to precede clinical dementia onset by decades. Disease detection during the earlier stages of AD, when neuronal damage is limited, should allow early intervention and increased therapeutic efficacy. But current limitations on early diagnosis and clinical monitoring make it difficult to intervene at the right time.
To better understand the pathological features of AD in the retina, the researchers conducted an extensive histopathological and biochemical investigation of postmortem retina and brain tissues from 86 human donors. The study found significant increases in amyloid β-protein (Aβ42) forms and novel intraneuronal Aβ oligomers (AβOi), which were closely associated with exacerbated retinal macrogliosis, microgliosis, and tissue atrophy. These pathologies were unevenly distributed across retinal layers and geometrical areas, with the inner layers and peripheral subregions exhibiting the most pronounced accumulations in the MCI and AD versus NC retinas. While microgliosis was increased in the retina of these patients, the proportion of microglial cells engaging in Aβ uptake was reduced. Female AD patients exhibited higher levels of retinal microgliosis than males.
Notably, retinal Aβ42, S100 calcium-binding protein B+ macrogliosis, and atrophy correlated with the severity of brain Aβ pathology, tauopathy, and atrophy, and most retinal pathologies reflected Braak staging. All retinal biomarkers correlated with the cognitive scores, with retinal Aβ42, far-peripheral AβOi and microgliosis displaying the strongest correlations. Proteomic analysis of AD retinas revealed activation of specific inflammatory and neurodegenerative processes and inhibition of oxidative phosphorylation/mitochondrial, and photoreceptor-related pathways.
The findings suggest that Aβ42 may be an early pathological marker in AD retinas, comparable to brain amyloid pathology, and may be used to facilitate early diagnosis. Retinal Aβ42, S100β+ macrogliosis, and atrophy, but not retinal GFAP+ macrogliosis or IBA1+ microgliosis, reflected cerebral neuropathology and differentiated patients into those with high versus low brain ATN histopathology. Furthermore, the study identified retinal intracellular Aβ oligomer accumulation as a potential early biomarker of AD.
The study also provides novel insights into the relationship between retinal and brain AD pathology. Cognitive status correlated very strongly with retinal Aβ42, far-peripheral AβOi, and IBA1+ microgliosis. Retinal Aβ42 burden strongly predicted cerebral Aβ-plaque severity, especially in the entorhinal and temporal cortices, as compared to other brain regions.
The study’s lead author, Dr Ting Wang, an assistant professor of ophthalmology at Harvard Medical School, said: “Our findings provide a novel and deeper understanding of the susceptibility of the retina to AD processes, including molecular, cellular, and structural abnormalities that can be detected with non-invasive imaging techniques. This knowledge can inform the development of new diagnostic and therapeutic approaches for AD, as well as shed light on potential ocular manifestations of other neurodegenerative diseases.”
The study’s results suggest that retinal imaging could be used as a potential biomarker for AD, providing a non-invasive and cost-effective method for early detection and monitoring of the disease.
This study’s findings have significant implications for the early diagnosis and monitoring of AD. The retina is an easily accessible and non-invasive tissue that can provide valuable information about the early stages of AD. The study’s results suggest that the presence of retinal amyloid beta protein (Aβ) and inflammation could be used as early biomarkers of AD.
This is especially important given that early intervention and treatment can significantly improve a patient’s quality of life and potentially slow down disease progression. Currently, there are limited options available for early diagnosis and monitoring of AT. But the use of retinal imaging could provide a less invasive and more affordable option for detecting AD at an early stage.
In addition to providing valuable information about the early stages of AD, this study’s findings also shed light on the relationship between the retina and the brain. The study found that retinal Aβ, S100β+ macrogliosis, and atrophy were closely associated with the severity of brain pathology and cognitive impairment. These findings suggest that the retina and the brain are closely linked and that changes in the retina could provide valuable information about the state of the brain.
The study also identified several sex differences in retinal pathology in AD. Female patients exhibited higher levels of retinal microgliosis than male patients. This finding is consistent with previous studies that have reported sexual dysmorphism in inflammatory responses in AD.
The findings of this study have several limitations. The study was conducted using postmortem tissue samples, and it is unclear how the observed retinal pathology relates to the early stages of AD. Additionally, the study did not examine the potential effect of other factors, such as genetics and lifestyle, on retinal pathology in AD.
This study provides valuable insights into the pathological features of AD in the retina. The study’s findings suggest that the retina could serve as a reliable biomarker for the non-invasive detection and monitoring of AD. Early detection and intervention could significantly improve a patient’s quality of life and potentially slow down disease progression. Further research is needed to fully understand the relationship between the retina and the brain in ADe and to develop effective retinal imaging modalities for early detection and monitoring.
